"Never Stop", "International Big Boss Walking in China | Pharmaceuticals | China | Boss
According to Taiwan's "China Times News Network" on June 5th, the State Council Information Office held a routine policy briefing to introduce the construction of a unified national market. At the briefing, officials from the Ministry of Commerce stated that they will continue to expand market access and further cancel or relax restrictions on foreign investment access.
Zhou Qiang, Director of the Market System Construction Department of the Ministry of Commerce, stated that building a unified large market is a globally oriented and fully open market, which will provide a better environment and a larger stage for various market entities, including foreign-funded enterprises. The Ministry of Commerce will promote high-level opening-up to the outside world in accordance with the requirements of the Central Economic Work Conference of the Communist Party of China. Leveraging China's super large market advantage, it will attract global resource elements through domestic circulation. It is necessary to retain high-quality stock foreign investment and attract more high-quality foreign investment to improve the quality and level of trade and investment cooperation.
Zhou Qiang stated that in the next step, the Ministry of Commerce will actively promote the construction of a unified national market and make greater efforts to attract and utilize foreign investment.
On June 3rd, the website of the French magazine "Viewpoint" reported that international tycoons have resumed contact with China.
The report states that the big bosses are constantly moving around in China. Since February, executives from large overseas companies have visited China every week to reconnect with markets and teams they haven't seen in the past three or four years.
The report goes on to say that the past week has been no exception, with Elon Musk visiting Beijing and Shanghai. This Tesla boss is a symbol in many ways.
Firstly, he is an American. Secondly, he represents several economic sectors that are fiercely competitive between the two economic powers: batteries, electric vehicles, and conquering space. It was in Shanghai that this American corporate executive established Tesla's first super factory outside of the United States. His ambition did not stop there. In April, Tesla announced the signing of a contract to build a factory in Shanghai to produce energy storage batteries.
Apple CEO Tim Cook went to China in March this year and participated in the highly influential China Development Forum. Recently, executives from JPMorgan Chase Bank, Pfizer Pharmaceuticals, and coffee chain Starbucks have once again set foot on the land of China.
The French are not lagging behind either. Luxury giants have long restored their connection to this market, which accounts for one-third of the industry's revenue. In the industrial sector, leaders of companies that have been operating in China for a long time, such as Jean Pascal Triquar, Chairman and CEO of Schneider Electric Investment Co., Ltd., and Bernua Bazan, CEO of Saint Gobain, have also reconnected with the world's second-largest economy. The delegation accompanying French President Macron on his visit to China in April included many executives from the top 40 listed companies in France.
The report further states that currently, it is difficult to bypass the world's second-largest economy and its unparalleled supply chain in many fields. Beijing's technological ambition and long-term vision will help China maintain its comparative advantage in the coming years.
The report believes that the idea of trying to "weaken" business activities in China is facing a real test. As Ni Yili, President of McKinsey&Company China, said, "The next China is China.".
On June 4th, the Financial Times website reported that AstraZeneca ignored geopolitics and bet on China.
According to reports, Pascal Sorio, CEO of AstraZeneca Pharmaceuticals, recently visited China and has now returned to his home country. He is excited about the explosive growth of Chinese biotechnology companies and the potential for his company to export drugs discovered in China to the world.
Although the G7 warns that China may engage in "economic coercion" and the United States is rigorously reviewing Chinese investments in the biotechnology sector, AstraZeneca is still focused on leveraging its position as China's largest foreign pharmaceutical company.
AstraZeneca Pharmaceuticals believes that opportunities lie not only in the Chinese market, but also in Chinese scientists. Michel de Mare, the new chairman of the company's board of directors, said, "They really have the ability to innovate and invest all their funds. There are many startups, and we are also involved."
According to reports, foreign pharmaceutical companies often believe that cooperation in China is safer than acquisitions due to concerns about political risks and intellectual property issues. But Sorio said in April that the company has "no restrictions" on acquiring Chinese companies.
In addition to Beijing, Shanghai, and the biotechnology center Suzhou, the company has also established contacts with other local governments.